CClinicalTrials.gg
Not yet recruitingNCT07012551Updated Jun 10, 2025

Endovascular Modalites for Contralateral Common Iliac Artery in Patients With Symptomatic Unilateral Common Iliac Artery Occlusive Disease

An observational study in Iliac Artery Disease, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

To evaluate the safety, efficacy, and outcomes of endovascular strategies for protection of the contralateral CIA in patients with symptomatic unilateral CIA occlusive disease

02

Conditions studied

  • Iliac Artery Disease
03

In context

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients attending the Vascular Surgery Clinics in Assiut University Hospitals complaining of unilateral CIA ostial occlusive disease, Rutherford category 3, 4and 5 will be recruited to participate in the study.

Inclusion criteria

  • Symptomatic patients (Rutherford category 3- 5) due to Unilateral common iliac artery occlusive disease.

with or without combined iliac or femoropopliteal or infrapopliteal lesions.

Asymptomatic Contralateral limb.

Patent at least one run-off vessel

Exclusion criteria

Exclusion Criteria:

  • Distal aorta lesion

contralateral CIA occlusion

Previous endovascular or surgical procedures for the same lesion

Hypersensitivity to contrast material

Presence of aortic or iliac aneurysms

Patients with unsalvageable limb

Non atherosclerotic lesions

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • ProcedureCommon iliac artery stenting

    Stenting of common iliac artery by balloon mounted stent

06

What researchers measure

Primary outcomes

  1. Primary patency of both common iliac arteries

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010 Mar 2;55(9):898-903. doi: 10.1016/j.jacc.2009.09.055. PubMed 20185041 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07012551
Lead sponsor
Assiut University
Responsible party
Abdelrahman Ahmed Shawki Roshdi (assistant lecturer, Assiut University) — Principal investigator
First posted
Jun 10, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jun 10, 2025

Study contacts

abdelrahman eltokhey
Contact
abdelrahmaneltokhey11@gmail.com
01003830585
mahmoud ismail
Contact
mahmoudismail79@yahoo.com
0106228283

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion